Search research articles
Contact Us
Filters
Showing results (301-310 of 415) with videos related to
Page
of 42
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
May 27, 2022
Immunocompromised patients have been neglected in COVID-19 trials: a call for action
Marius Trøseid, Maxime Hentzien, Florence Ader, et al.
Thrombosis Research
|
February 21, 2023
Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial
Olivier Pantet, Christophe Combescure, Zied Ltaief, et al.
The Journal of Infectious Diseases
|
May 10, 2020
Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study
Jan A Roth, Gorjan Radevski, Catia Marzolini, et al.
The Journal of Infectious Diseases
|
February 22, 2015
The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals
Molly R Perkins, Istvan Bartha, J Katherina Timmer, et al.
JMIR Mhealth and Uhealth
|
November 14, 2019
Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African Countries
Phillipe Lepère, Yélamikan Touré, Alexandra M Bitty-Anderson, et al.
Open Forum Infectious Diseases
|
June 6, 2018
The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis
Alex Marzel, Katharina Kusejko, Rainer Weber, et al.
American Journal of Epidemiology
|
August 1, 2013
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study
Barbara Bertisch, Silvia Franceschi, Mauro Lise, et al.
The Lancet. HIV
|
May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
Pharmacogenetics and Genomics
|
February 9, 2010
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
Rubin Lubomirov, Julia di Iulio, Aurélie Fayet, et al.
AIDS (London, England)
|
July 19, 2014
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients
Karin J Metzner, Alexandra U Scherrer, Viktor von Wyl, et al.
Page
of 42
Search research articles
Search
Showing results (301-310 of 415) with videos related to
Sort By:
Page
of 42
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
May 27, 2022
Immunocompromised patients have been neglected in COVID-19 trials: a call for action
Marius Trøseid, Maxime Hentzien, Florence Ader, et al.
Thrombosis Research
|
February 21, 2023
Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial
Olivier Pantet, Christophe Combescure, Zied Ltaief, et al.
The Journal of Infectious Diseases
|
May 10, 2020
Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study
Jan A Roth, Gorjan Radevski, Catia Marzolini, et al.
The Journal of Infectious Diseases
|
February 22, 2015
The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals
Molly R Perkins, Istvan Bartha, J Katherina Timmer, et al.
JMIR Mhealth and Uhealth
|
November 14, 2019
Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African Countries
Phillipe Lepère, Yélamikan Touré, Alexandra M Bitty-Anderson, et al.
Open Forum Infectious Diseases
|
June 6, 2018
The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis
Alex Marzel, Katharina Kusejko, Rainer Weber, et al.
American Journal of Epidemiology
|
August 1, 2013
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study
Barbara Bertisch, Silvia Franceschi, Mauro Lise, et al.
The Lancet. HIV
|
May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
Pharmacogenetics and Genomics
|
February 9, 2010
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
Rubin Lubomirov, Julia di Iulio, Aurélie Fayet, et al.
AIDS (London, England)
|
July 19, 2014
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients
Karin J Metzner, Alexandra U Scherrer, Viktor von Wyl, et al.
Page
of 42